We conducted a phase II study of ifosfamide and etoposide chemotherapy in patients with untreated extensive-disease small-cell lung cancer to assess response and toxicity. Between January 1994 and December 1995, 16 patients were treated. Ifosfamide and etoposide doses were ifosfamide 2 g/m 2 , with mesna, i.v. infusion over 30 minutes on days 1-3 and etoposide 80 mg/m 2 i.v. over 120 minutes on days 1-3 every 4 weeks for up to six cycles. All patients were evaluable for toxicity profile and treatment response. As expected, the major toxicity was myelosuppression. With one exception, grade 3 or 4 leukopenia occurred in all patients during treatment, and 48.7% of the total courses had grade 3 or 4 leukopenia. Nine of 16 patients (56.3%) experienced episodes of febrile neutropenia. One toxic death due to febrile neutropenia with sepsis was documented. Toxicities other than leukopenia were few and mild in severity. After two cycles of treatment, the overall response rate was 81.3% (95% confidence interval 62.2-100) in this study. The median duration of response was 8 months and median survival was 11 months. In conclusion, ifosfamide and etoposide is an active combination regimen with acceptable toxicity profile in Chinese patients with extensive-disease small-cell lung cancer.
INTRODUCTION
Small-cell lung cancer (SCLC) accounts for 15% (425/3327 from 1989 to 1993) of lung cancer patients diagnosed in our hospital (1) . Combination chemotherapy, in particular etoposide and cisplatin (EP), has become the standard therapy for this disease. However, in spite of significant initial advances in the treatment of this disease in the past two decades, patients with extensive disease (ED) SCLC continue to have a poor prognosis. They generally have a complete response (CR) rate of <30% and a median survival duration of 7-11 months, with almost all patients dead within 2 years (2-4). Therefore, the emergence of newer compounds and the better use of old ones has provided potentially important issues to be explored in ED SCLC.
Ifosfamide is an analogue of the alkylating agent cyclophosphamide, with different pharmacokinetics and metabolism compared to its parent compound (5) (6) (7) . Ifosfamide has significant activity as a single agent in previously untreated SCLC with overall response rates (RR) of 50-60% cited (8) . In an Eastern Cooperative Oncology Group (ECOG) phase III study, an overall RR of 49% and a median survival time of 43 weeks were observed in the ifosfamide arm, which was no different from the other two arms (single agent teniposide or a combination of cyclophosphamide, doxorubicin and vincristine) (9, 10) . The introduction of mesna, which specifically abolishes the urotoxicity, together with decreased myelotoxicity in comparison to cyclophosphamide (11) , has allowed its inclusion in more aggressive combination regimens for SCLC.
Etoposide, a topoisomerase II inhibitor, has become a first line drug in the treatment of SCLC and the reported overall RR in untreated patients was approximately 50% or higher (12, 13) . Combination chemotherapy with ifosfamide and etoposide in SCLC had been reported previously from western countries (14, 15) . However, information from Chinese patients has been scarce. Here, we report the results of a phase II study in untreated ED SCLC, in which we combined i.v. ifosfamide and etoposide (IE) on days 1-3 every 4 weeks. The objective of this study was to evaluate the overall response rate, duration of response, toxicity profile and effect on median survival time for our Chinese patients.
SUBJECTS AND METHODS

ELIGIBILITY CRITERIA
All patients entered onto this trial had histologically confirmed SCLC or an unequivocally positive cytologic specimen. Patients must have had measurable ED, as defined by disease beyond the hemithorax and adjacent nodes, pleural effusion with positive cytology, or superior vena cava (SVC) syndrome. Patients with brain metastases were eligible provided that they had received cranial irradiation or were asymptomatic. No patients with previous chemotherapy or radiation therapy to the primary lesion were included. All patients were required to have an ECOG performance status (PS) of 0-3. Other eligibility criteria included a WBC count w3000/mm 3 , platelet count w100 000/mm 3 , serum bilirubin level v3.0 mg/dl, serum aspartate aminotransferase (AST) level t180 IU/l and serum creatinine level v2 mg/dl. Patients with previous or concurrent malignancy (other than curatively treated basal cell or squamous cell skin cancer or carcinoma-in-situ of the cervix), active infection, uncontrollable congestive heart failure or myocardial infarction v6 months before entry were ineligible.
PRETREATMENT EVALUATION
Patients were required to have a complete history and physical examination, hemogram, chemical analysis, urinalysis, chest x-ray and CT scan, bone scan, brain CT or brain scan and bone marrow aspiration and biopsy if possible. A bronchoscopy was not required at diagnosis if the diagnosis had been established by other means. Before study entry, all patients gave written, informed consent that indicated their awareness of the investigative nature of this protocol, which had been approved by ethical review boards.
TREATMENT PLAN
Patients were treated with up to six cycles of IE at 4-weekly intervals. Ifosfamide (2 g/m 2 ) i.v. was infused over 30 minutes on days 1-3. Mesna (400 mg/m 2 ) was given i.v. at 0, 4 and 8 hours after the beginning of ifosfamide infusion. Etoposide (80 mg/m 2 ) was given i.v. over 120 minutes on days 1-3. Lorazepam, primperan and decadron were given half an hour before chemotherapy on these 3 days. Urinalysis was done on days 1-4. All patients receiving chemotherapy were admitted for 4 days in every course of treatment.
Subsequent doses were modified on the basis of hematologic and non-hematologic toxicities. Routine history, clinical examination, chemical analysis, hematology, urinalysis and chest x-ray were repeated before treatment. If the WBC count was t3000/mm 3 or platelet count was t100 000/mm 3 , therapy was delayed by one week until recovery to greater than these levels (checked weekly). Dose adjustments, interruptions and discontinuations were also made if the nadir WBC count was t1000/mm 3 or platelet count was t25 000/mm 3 (ifosfamide, mesna and etoposide), the serum creatinine level was >1.5 mg/dL (ifosfamide and mesna), the serum AST level >300 IU/L or bilirubin level >3.0 mg/dL (ifosfamide, mesna and etoposide), or for hemorrhagic cystitis (ifosfamide and mesna). Patients were taken off study in the case of neurotoxicity of grade 3 or higher or of other grade 4 non-hematological toxicities. The use of growth factors was allowed only in management of febrile neutropenia. DURATION OF THERAPY Therapy consisted of a maximum of six cycles given every 4 weeks. If disease progression occurred or there was stable disease after three cycles, patients were taken off study. Patients who achieved only a partial response (PR) continued on therapy until completion of six cycles of treatment or disease progression. Patients in complete response (CR) received at least six cycles, or two additional cycles beyond the cycle at which the CR was obtained. Prophylactic cranial irradiation (PCI) was optional in patients who achieved CR. PCI consisted of a total dose of 25 Gy administered in 10 fractions of 2.5 Gy. In addition to routine follow-up in the outpatient clinic in midcycle, the patients were advised to contact the hospital if they felt unwell between chemotherapy courses. Appropriate tests and care were undertaken upon their visit to our clinic or emergency room.
EVALUATION DURING TREATMENT AND RESPONSE CRITERIA Patients underwent a clinical evaluation before each cycle, as well as urinalysis, hemogram (also performed in midcycle) and chemical measurments. Chest x-rays were obtained before each cycle. In patients with lesion(s) only assessable with chest CT scans, the scans were repeated before each cycle or every other cycle. All initially positive studies were repeated as clinically indicated, but were mandatory at the time that a patient was considered to be in clinical CR. Patients who completed therapy were monitored every month. Types of response and severity of toxicity were assessed according to established ECOG criteria (16) . The median survival time and duration of response was calculated according to the Kaplan-Meier method. 
RESULTS
PATIENTS
Between January 1994 and December 1995, 16 patients were accrued onto this study (Table 1) . Except for one female patient, all Figure 1 . The Kaplan-Meier survival curve of 16 extensive-disease small-cell lung cancer patients treated with ifosfamide and etoposide. The median survival time was 11 months (95% confidence interval 7.5-14.5 months). Of these patients, eight died during the treatment or follow-up periods, one was lost from the follow-up 5 months after entering the study and the remaining seven patients were still alive at the end of August 1996.
were male. All were assessable for toxicity profile and treatment response.
THERAPEUTIC RESULTS
All patients were assessable for treatment response. A total of 78 cycles of IE were given before the end of June 1996. The mean and median number of cycles per patient were 5 and 6 respectively (range 1-6). A total of 13 out of 16 patients treated had objective responses (81.3%; 95% confidence interval 62.2-100), with 2 patients achieving CR and 11 patients PR ( Table 2 ). The first patient who achieved CR refused fiberoptic bronchoscopy follow-up. However, he received prophylactic cranial irradiation. He survived 20.5 months from the beginning of treatment. The median duration of response was 8 months and median survival time was 11 months (Fig. 1) .
TOXICITY
As expected, myelotoxicity was the most important toxicity, particularly leukopenia (Table 3) . Grade 3 or 4 leukopenia occurred in 48.7% of cycles given to the patients. All patients except one experienced grade 3 or 4 leukopenia during the IE treatment. Nine of 16 patients (56.3%) had a history of febrile neutropenia during the course of treatment. One patient died of sepsis due to grade 4 leukopenia during his first course of therapy in spite of granulocyte-colony stimulating factor (G-CSF) and antibiotic treatment. Thrombocytopenia was not a serious problem in this study. There were several other nonhematologic toxicities, which, for the most part, were not a limiting factor in the administration of IE. Grade 3 nausea occurred in six of 78 cycles of treatment and grade 3 vomiting occurred in four of 78 cycles of treatment. Diarrhea occurred in only one patient. Grade 1 or 2 mucositis occurred in eight of 78 cycles of treatment. Five patients suffered from reversible grade 1 renal toxicity (10 in 78 cycles). One patient had grade 1 haematuria and one patient had grade 2 haematuria during the treatment. No neurologic, cardiac or pulmonary toxicity was found during the study. Alopecia occurred in 56.3% of the patients.
DISCUSSION
In past decade, there has been a lack of significant improvement in the survival of patients with ED SCLC. Combination chemotherapy with cisplatin and etoposide (PE) (replacing cyclophosphamide, adriamycin and vincristine [CAV]) became the standard therapy, while new concepts and approaches were being tested. Among them were the use of dose-intensive regimens, alternating chemotherapy regimens and high-dose chemotherapy with autologous bone marrow rescue (2) . Many of these regimens attained an improved response rate, sometimes at the cost of significant toxicity, but without any success in improving the overall survival of patients with ED.
We report the results of a phase II study of an IE regimen, designed to explore the combination of two active drugs, ifosfamide and etoposide. Etoposide has been a well accepted standard chemotherapeutic agent in treating SCLC, including usage in Taiwan. While ifosfamide has been used frequently in recent years to treat SCLC since its development in Germany in 1965 (10, 17, 18) , its use in Taiwan for SCLC is still random and infrequent. Concerning the dosage and schedule of the drugs used in this clinical trial, etoposide was scheduled at 80 mg/m 2 on days 1-3 because in our previous clinical trials in lung cancer, it was used as such in combination with cisplatin. As regards ifosfamide, when used as a single agent a dose of 2.4 gm/m 2 on days 1-3 had been found to be a tolerable dose with acceptable toxicity for a phase II trial in nasopharyngeal carcinoma, so when used in combination with etoposide, a myelosuppressive agent, ifosfamide was reduced to 2 gm/m 2 on days 1-3 to allow for the combined myelosuppression.
An early German trial combining IE in 41 SCLC patients with ED and limited disease (LD) attained an overall response rate of 84% and a median survival of 18 months for LD patients and 10 months for ED patients (19) . Based on these encouraging results, a number of investigators began to study IE for the treatment of patients with SCLC. Thatcher et al., from Manchester, England, examined this combination in both LD and ED patients (14) . The protocol consisted of ifosfamide, 5 g/m 2 as a 24-hour i.v. infusion, with mesna uroprotection on day 1, and etoposide, 120 mg/m 2 i.v. on days 1 and 2 plus 240 mg/m 2 orally on day 3; the courses were given at 3-week intervals. There were 85 ED patients treated. ED patients achieved a CR rate of 27% and a PR rate of 38%, with a median survival of 8 months. Concerning toxicity, LD and ED are discussed together. When considering ED and LD patients together, 6% of courses led to grade 3 or 4 leukopenia. There were two toxic deaths among 163 patients. Nausea/vomiting was rarely severe, with 79% of courses having mild or no gastrointestinal side effects. In our series, 48.7% of courses had grade 3 or 4 leukopenia and 15.4% of courses had febrile neutropenia. The reasons for a relatively higher dose intensity and less myelosuppression in their series when compared with ours was probably due to the fact that all of our patients were in a later stage of SCLC and more patients had a poor performance status. Another possibility is due to different scheduling and dosage of ifosfamide given. In spite of a lower dose intensity and higher myelosuppression in our patients, a higher response rate was noted from our patients and toxic death was 6.3% in our series. The median duration of response (8 months) and median survival time of 11 months were also similar to or better than previous reports (14, 19) . Regarding other toxicities in our patients, most patients were free from vomiting or had only mild nausea/vomiting, few patients had diarrhea or mucositis, few had renal function impairment or haematuria, and hepatic dysfunction was rare. No pulmonary, cardiac or neurologic dysfunction was noted.
Wolf et al. (20) treated 144 patients with SCLC in a multicenter randomized study comparing IE (ifosfamide/etoposide) with PE (cisplatin/etoposide). IE consisted of ifosfamide 1.5 g/m 2 IV on days 1 to 5 and etoposide 120 mg/m 2 IV on days 3 to 5. Chemotherapy was administered at 3-week intervals. Nonresponders received CAV. The overall response rate was 68% in patients receiving IE and 65% in patients receiving PE. In ED patients receiving IE or PE, the CR rates were 18% and 22% and the median survival times 7.5 and 8.9 months respectively. Myelosuppression was slightly higher with IE than with PE therapy. However, the latter was complicated by a higher frequency of nausea, vomiting, diarrhea and skin lesions. The investigators felt that these results suggest that PE is superior to IE in LD SCLC patients, but not in ED SCLC patients.
In summary, our clinical trial showed that use of IE in Chinese ED SCLC gave a high overall response rate with an acceptable toxicity profile. The main toxicity was reversible myelosuppression, especially leukopenia. Thrombocytopenia was rare. Further phase III randomized trials comparing IE with EP is needed in ED SCLC. However, a very large number of patients is probably needed to achieve a statistically significant difference or adequate power.
